939-07-1

Basic information

• Product Name: 5-phenyl-1,2-dihydro-3H-1,2,4-triazol-3-one
• Synonyms: 1H-1,2,4-triazol-3-ol, 5-phenyl-; 3-phenyl-1H-1,2,4-triazol-5-ol; 5-phenyl-1H-1,2,4-triazol-3-ol
• CAS NO: 939-07-1
• Molecular Formula: C₈H₇N₃O
• Molecular Weight: 161.1607
• Mol File: 939-07-1.mol
• Article Data: 20

Chemical Properties

• Density: 1.39g/cm³
• Refractive Index: 1.692
• CAS DataBase Reference: 5-phenyl-1,2-dihydro-3H-1,2,4-triazol-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 5-phenyl-1,2-dihydro-3H-1,2,4-triazol-3-one(939-07-1)
• EPA Substance Registry System: 5-phenyl-1,2-dihydro-3H-1,2,4-triazol-3-one(939-07-1)

Safety Data

• Hazardous Substances Data: 939-07-1(Hazardous Substances Data)

Usage

General Description

5-phenyl-1,2-dihydro-3H-1,2,4-triazol-3-one, also known as PHT, is a chemical compound that belongs to the class of triazolones. It has the molecular formula C9H9N3O and a molecular weight of 175.19 g/mol. PHT is a white to off-white solid that is soluble in organic solvents but insoluble in water. It is known for its pharmacological activities, including anticonvulsant, anxiolytic, and sedative properties. PHT is used in pharmaceutical research and development as a potential candidate for the treatment of various neurological disorders, and it is also used as a precursor in the synthesis of other organic compounds. However, PHT may also have potential hazards and health effects, so it should be handled and used with caution in a laboratory or industrial setting.

Upstream product

• 62036-20-8 3-ethoxy-5-phenyl-1,2,4-triazole 
• 2845-79-6 1-benzoyl semicarbazide 
• 16956-44-8 N,2-dibenzoylhydrazine-1-carboxamide 
• 123-77-3 Azodicarboxamid 
• 100-52-7 benzaldehyde 
• 1574-10-3 benzaldehyde semicarbazone 
• 1612-76-6 2-amino-5-phenyl-1,3,4-oxadiazole 
• 75119-50-5 1,2,2,2-tetrachloro-1-phenylethyl isocyanate 
• 101934-62-7 Ethyl N-(methoxycarbonyl)-benzenecarboximidate 
• 827-44-1 5-chloro-3-phenyl-1,2,4-oxadiazole 
• 124-38-9 carbon dioxide 
• 28819-30-9 benzamidrazone 
• 563-41-7 semicarbazide hydrochloride 
• 1663-61-2 triethoxymethylbenzene 

Downstream Products

• 3414-94-6 5-phenyl-4H-1,2,4-triazol-3-thiol 
• 291310-97-9 4-(5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-benzenesulfonyl chloride 
• 1256844-25-3 C₁₆H₁₃N₃O₂ 
• 246848-34-0 C₁₅H₁₃N₃O₂ 
• 19081-61-9 1-(4-methylphenyl)-3-phenyl-1,2,4-triazol-5-one 
• 1256844-26-4 C₁₅H₁₀N₄O 
• 50369-39-6 4-methyl-3-phenyl-Δ²-1,2,4-triazolin-5-one 
• 78414-70-7 1-benzylideneamino-3-phenyl-Δ²-1,2,4-triazolin-5-one 
• 78414-76-3 1-amino-4-methyl-3-phenyl-Δ²-1,2,4-triazolin-5-one 
• 78414-73-0 1-amino-5-methoxy-3-phenyl-1,2,4-triazole 

Relevant articles and documents

TRIAZOLONES DERIVATIVES FOR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, tautomer, racemate, codrug, cocrystal, enantiomer, or diastereomer or mixture thereof, which is useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

Design, synthesis, and biological activity of novel tetrahydropyrazolopyridone derivatives as FXa inhibitors with potent anticoagulant activity

A series of novel tetrahydropyrazolopyridone derivatives containing 1,3,4-triazole, triazolylmethyl, and partially saturated heterocyclic moieties as P2 binding element was designed, synthesized, and evaluated in vitro for anticoagulant activity in human and rabbit plasma. All compounds showed moderate to significant potency, and compounds 15b, 15c, 20b, 20c, and 22b were further examined for their inhibitory activity against human FXa in vitro. While compounds 15c and 22b were tested for rat venous thrombosis in vivo. The most promising compound 15c, with an IC50 (FXa) value of 0.14?μM and 98% inhibition rate, warranted further investigation as an FXa inhibitor.

Chlorosulfonation of some crisscross cycloadducts from isocyanates and diaryl azines

Reaction of chlorosulfonyl isocyanate (1) with arylaldehyde azines (7) gave the 2:1 crisscross adducts (8); attempts to prepare a disulphonamide of 8a gave only a mixture of the monosulfamide 9 and the diureide 10. The latter with trichloromethanesulfenyl chloride afforded the derivative 12a, and with chlorosulfonic acid hydrazinodicarbonamide (11). The azine 7a with benzoyl isocyanate (2) gave the expected crisscross adduct 13. With thiobenzoyl isocyanate (3) however, both 7a and 7d gave the 1:1 adducts (14), whereas 7c gave a different 2:1 adduct (15). Treatment of 14a with 1 gave the ureide 16. With both methyl isocyanate (4) and phenyl isocyanate (5), 7a gave the expected crisscross adducts (17a and b), and 7c with 5 similarly gave 17c. When 7a was treated with 1 followed by aqueous potassium iodide, the diureide (10) was formed; concentrated nitric acid converted 10 into the triazolenone (18). Treatment of 18 with chlorosulfonic acid-thionyl chloride gave the sulfonyl chloride (19) which was characterised as the sulfonamides (20 a-d). Diarylsulfamoyl azines (21 a-f) with 1 and potassium iodide, gave the diureides 22 a-f. 4-Methoxy-3-sulfamoylbenzaldehyde azines (23 a-c) reacted with 3 to give the 1:1 adducts 24 a-c, while 4-chlorosulfonylphenyl isocyanate (6) with benzaldehyde azine (7a) gave the bis-chlorosulfonyl adduct (25a), characterised as the diethylsulfonamide 25b. Attempted chlorosulfonation of the tetraphenyl cycloadduct 17b did not give the tetrasulfonyl chloride (although the reaction was successful with the more reactive methoxy adduct 17c); the tetrasulfonyl chloride (26a) was converted into 3 sulfonamides (26 b-d). The unsymmetrically-substituted diaryl azines (27) reacted with 1 and potassium iodide to yield the diureides 28 a-f. Analogous cycloadditions of 1 with several keto azines were unsuccessful. Selected compounds will be screened for medicinal and pesticidal activity: compounds 9, 10 and 12a showed fungicidal activity against barley powdery mildew.